Douat J, Ancele E, Cournot M, Pagot-Mathis V, Mathis A, Quintyn J C
Service d'Ophtalmologie, CHU Rangueil, Toulouse.
J Fr Ophtalmol. 2007 Dec;30(10):1007-12. doi: 10.1016/s0181-5512(07)79278-1.
Evaluate the effects of hemodilution in the treatment of central retinal vein occlusion (CRVO).
We carried out a retrospective, noncomparative study of 25 patients presenting unilateral CRVO, treated with one to three hemodilution sessions. The patients were re-examined in the 1st, 2nd, 3rd, 6th and 12th months following treatment with measurement of visual acuity, fluorescein angiography, and optical coherence tomography.
Our study included 17 men and eight women, averaging 63 years of age (range, 35-87 years), and monitored for an average of 7 months (range, 3-12 months). After the 6th month following treatment, average visual acuity improved compared to initial visual acuity. Initial visual acuity of less than 1/10, with the existence of poorly irrigated areas in the angiography, presented negative prognosis factors. The number of hemodilutions did not produce a significant difference in final visual acuity. No serious complications due to hemodilution were observed.
Treatment of CRVO is subject to debate. Some practitioners recommend against treatment, while others advocate intervention and offer laser-induced chorioretinal venous anastomosis. Surgical vitrectomy and radial optical neurotomy, with or without injection of triamcinolone, await evaluation. Hemodilution may offer a therapeutic approach to this pathology, in which the etiopathogenesis is not yet recognized, but in which blood viscosity plays a key role. This treatment is well tolerated.
Hemodilutions appear to have beneficial effects in treating CRVO, whatever the number of hemodilutions used. This study should be confirmed by a prospective study using an untreated control group.
评估血液稀释疗法在治疗视网膜中央静脉阻塞(CRVO)中的效果。
我们对25例单侧CRVO患者进行了一项回顾性、非对照研究,这些患者接受了一至三次血液稀释治疗。在治疗后的第1、2、3、6和12个月对患者进行复查,测量视力、荧光素血管造影和光学相干断层扫描。
我们的研究包括17名男性和8名女性,平均年龄63岁(范围35 - 87岁),平均随访7个月(范围3 - 12个月)。治疗后第6个月,平均视力较初始视力有所提高。初始视力低于1/10且血管造影中存在灌注不良区域是不良预后因素。血液稀释的次数对最终视力没有显著差异。未观察到因血液稀释引起的严重并发症。
CRVO的治疗存在争议。一些从业者不建议治疗,而另一些人则主张干预并提供激光诱导脉络膜视网膜静脉吻合术。手术玻璃体切除术和放射状视神经切开术,无论是否注射曲安奈德,均有待评估。血液稀释可能为这种尚未明确发病机制但血液粘度起关键作用的病理状况提供一种治疗方法。这种治疗耐受性良好。
无论进行多少次血液稀释,血液稀释疗法在治疗CRVO中似乎都有有益效果。本研究应通过使用未治疗对照组的前瞻性研究来证实。